TORNTPHARM — Torrent Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- IN₹866.35bn
- IN₹901.80bn
- IN₹96.20bn
- 96
- 11
- 98
- 83
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 76,728 | 79,393 | 80,048 | 85,080 | 96,202 |
Cost of Revenue | |||||
Gross Profit | 53,511 | 56,868 | 57,695 | 59,706 | 67,925 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 66,644 | 64,233 | 61,769 | 72,236 | 74,847 |
Operating Profit | 10,084 | 15,160 | 18,279 | 12,844 | 21,355 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 5,617 | 11,866 | 15,263 | 12,259 | 18,472 |
Provision for Income Taxes | |||||
Net Income After Taxes | 4,363 | 9,719 | 12,519 | 7,772 | 12,452 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 4,363 | 10,247 | 12,519 | 7,772 | 12,452 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 4,363 | 10,247 | 12,519 | 7,772 | 12,452 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 21.2 | 28.8 | 37 | 32 | 36.5 |
Dividends per Share | |||||
Special Dividends per Share |